07 December 2022 | Wednesday | News
Image Source : Public Domain
The new U.S. dataset will expand the real world data and analytics offerings from Clarivate. Researchers can access an in-depth view of high-cost medications and valuable insights into the patient's treatment journey in chronic, complex and rare diseases, such as rheumatoid arthritis (e.g., Humira, Enbrel), inflammatory conditions (e.g., Dupixent, Otezla), and cancer (e.g., Xgeva, Xeloda).
Specialty drugs cover at least 20% of the market for chronic, complex and rare diseases. However, conventional claims data warehouses rarely include these high-cost medications, which limits the research potential of numerous diseases. Specialty pharmacy data enables life sciences professionals to:
Researchers can leverage this real-world dataset to make evidence-based decisions -- developing successful strategies, optimizing commercial resources, and defining the right activities and messaging to improve patient outcomes.
Matt McKinley, VP, Head of Real World Data & Analytics, said: "Clarivate is committed to supporting customers across the drug, device and diagnostic lifecycle with timely, fit-for-purpose real world data solutions. The addition of integrated, high-capture specialty pharmacy data to the Clarivate portfolio further expands the set of questions that can be answered in the data by reducing fragmentation and bias and providing a more holistic view of the patient."
The specialty pharmacy data covers over 500 specialty drugs spanning diverse therapeutic areas. The data enables a holistic analysis of complex clinical profiles reducing the need for additional data mapping or processing. The unique data and insights are updated weekly, allowing users to track changes in clinical pathways, product uptake and market dynamics.